FIELDS of dreams, fields of tears: a perspective on the fibrate trials

International Journal of Clinical Practice
Anthony S Wierzbicki

Abstract

Endpoint studies have been performed with fibrates in coronary heart disease since 1971. The results have been confusing - starting with initial benefits in small studies, but contradicted by either minimal benefits in the Coronary Drug Project or adverse noncardiovascular (non-CV) effects in the World Health Organization Clofibrate Study. Fibrates returned for patients with low HDL-C and low LDL-C after a 25% event reduction were seen in the Veterans Affairs HDL Intervention Trial. The greater prominence ascribed to the lipid triad of the metabolic syndrome and the increasing prevalence of diabetes increased the topicality of fibrates given their main action of converting small dense to light buoyant LDL. The Fenofibrate Intervention in Event Lowering in Diabetes (FIELD) Study has carried on the tradition. Fenofibrate therapy in 9795 patients comprising a mixed low-risk primary and a medium-risk secondary prevention cohort resulted in an 11% reduction in coronary events (p = 0.16), a similar but significant reduction in CV events (p = 0.04; number needed to treat = 70). The benefits were concentrated in primary prevention and on nonfatal myocardial events, but the study was confounded by asymmetrical statin drop-in due to the ...Continue Reading

References

Jan 27, 1975·JAMA : the Journal of the American Medical Association
Jan 1, 1994·Journal of Internal Medicine·J K HuttunenM H Frick
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jul 6, 2000·Circulation·UNKNOWN Bezafibrate Infarction Prevention (BIP) study
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Nov 16, 2002·BMJ : British Medical Journal·Tom MeadeJackie Cooper
Jun 20, 2003·Current Medical Research and Opinion·A S WierzbickiC B Byrne
Dec 2, 2004·JAMA : the Journal of the American Medical Association·Bruce M PsatyNoel S Weiss
Dec 28, 2004·The American Journal of Cardiology·Peter H Jones, Michael H Davidson
Jan 18, 2005·Journal of the American College of Cardiology·Rakesh S BirjmohunErik S G Stroes
Feb 8, 2005·The American Journal of Cardiology·Scott M GrundyJoanne Palmisano
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Apr 2, 2005·Current Medical Research and Opinion·Anthony S Wierzbicki
May 6, 2005·European Heart Journal·Alexander TenenbaumSolomon Behar
May 25, 2005·Archives of Internal Medicine·Alexander TenenbaumSolomon Behar
Aug 9, 2005·International Journal of Behavioral Medicine·Kristina Orth-GomérNeil Schneiderman
Sep 20, 2005·Cardiovascular Diabetology·Alexander TenenbaumEnrique Z Fisman
Oct 11, 2005·Lancet·Hannele Yki-Järvinen
Nov 17, 2005·JAMA : the Journal of the American Medical Association·Terje R PedersenUNKNOWN Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group

❮ Previous
Next ❯

Citations

Jan 9, 2007·Cardiovascular and Interventional Radiology·Anthony S Wierzbicki
Apr 12, 2007·Current Diabetes Reports·Marja-Riitta Taskinen
Oct 27, 2007·Antioxidants & Redox Signaling·Andrea M Vincent, Eva L Feldman
Jul 25, 2007·Diabetes, Obesity & Metabolism·A S Wierzbicki
Aug 31, 2006·International Journal of Clinical Practice·A S Wierzbicki
Sep 20, 2006·International Journal of Clinical Practice·Anthony S Wierzbicki
Jun 20, 2007·International Journal of Clinical Practice·Anthony S Wierzbicki
Jun 20, 2007·International Journal of Clinical Practice·Anthony S Wierzbicki
Jul 28, 2007·International Journal of Clinical Practice·E Bruckert, B Hansel
Oct 16, 2007·International Journal of Clinical Practice·A S Wierzbicki
Oct 16, 2007·International Journal of Clinical Practice·A S Wierzbicki
Jun 20, 2008·International Journal of Clinical Practice·A S Wierzbicki
Mar 16, 2011·International Journal of Clinical Practice·A S Wierzbicki
Oct 15, 2011·International Journal of Clinical Practice·Anthony S Wierzbicki
Jul 3, 2013·Current Cardiology Reports·James BarnettAnthony S Wierzbicki
Jan 27, 2011·The Journal of Nutrition, Health & Aging·A Viljoen
Oct 17, 2014·Expert Opinion on Pharmacotherapy·Anthony S Wierzbicki, Adie Viljoen
Jul 29, 2010·Current Medical Research and Opinion·Anthony S WierzbickiRichard Wray
Oct 31, 2006·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Marja-Riitta Taskinen
Jun 14, 2013·International Journal of Clinical Practice·A S Wierzbicki
Mar 31, 2015·International Journal of Clinical Practice·A Viljoen, A S Wierzbicki
Mar 5, 2010·Risk Analysis : an Official Publication of the Society for Risk Analysis·Ian DobsonKevin R Wierzbicki
Aug 22, 2016·Progress in Cardiovascular Diseases·Nidhi AgrawalIra J Goldberg
May 17, 2018·Diabetic Medicine : a Journal of the British Diabetic Association·A S Wierzbicki
May 31, 2018·Expert Review of Clinical Pharmacology·Rabia ChaudhryAnthony S Wierzbicki
Jul 14, 2010·Current Opinion in Lipidology·Anthony S Wierzbicki
Jun 14, 2019·Post Reproductive Health·John C Stevenson
Mar 31, 2012·Expert Review of Cardiovascular Therapy·Adie Viljoen, Anthony S Wierzbicki
May 9, 2012·Current Opinion in Cardiology·Anthony S WierzbickiDimitri P Mikhailidis
May 9, 2009·Current Opinion in Cardiology·Anthony S Wierzbicki
Jul 3, 2013·Journal of Cardiovascular Pharmacology and Therapeutics·Mfon Ewang-Emukowhate, Anthony S Wierzbicki
Apr 3, 2008·Menopause International·Margaret ReesUNKNOWN British Menopause Society Council

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.